Novo Nordisk’s Weekly Injection for Type 2 Diabetes, Ozempic, Set to Launch in India
Global healthcare company Novo Nordisk is preparing to introduce its weekly injection, Ozempic, for the treatment of type 2 diabetes in India. This development marks a significant advancement in diabetes care within the country.
Ozempic offers a convenient once-weekly dosing schedule, designed to help patients manage their blood sugar levels more effectively. The medication has been widely recognized for its efficacy and safety profile in clinical studies worldwide.
With the launch of Ozempic in India, Novo Nordisk aims to provide better treatment options for the growing number of individuals living with type 2 diabetes, enhancing their quality of life and disease management.
Further details regarding availability and pricing are expected to be announced soon, as the company moves forward with its plans to make Ozempic accessible to patients across India.